Peripheral Serotonin Synthesis as a New Drug Target

Susann Matthes¹,² and Michael Bader¹,²,3,4,5,*

The first step in serotonin (5-HT) biosynthesis is catalyzed by tryptophan hydroxylase (TPH). There are two independent sources of the monoamine that have distinct functions: first, the TPH1-expressing enterochromaffin cells (ECs) of the gut; second, TPH2-expressing serotonergic neurons. TPH1-deficient mice revealed that peripheral 5-HT plays important roles in platelet function and in inflammatory and fibrotic diseases of gut, pancreas, lung, and liver. Therefore, TPH inhibitors were developed which cannot pass the blood–brain barrier to specifically block peripheral 5-HT synthesis. They showed therapeutic efficacy in several rodent disease models, and telotristat ethyl is the first TPH inhibitor to be approved for the treatment of carcinoid syndrome. We review this development and discuss further therapeutic options for these compounds.

The 5-HT System Defined by TPH1 and TPH2

Initially discovered as a vasoconstricting substance in serum [1], the biogenic monoamine serotonin, 5-hydroxytryptamine (5-HT; see Glossary) is now known to be involved in a broad spectrum of physiological processes including behavior, vascular function, hemostasis, liver regeneration, gut motility, insulin secretion, erythropoiesis, mammary gland plasticity, adipocyte differentiation, immune responses, fibrosis, and heart and brain development [2–9]. For most of these functions the source of 5-HT in the brain is the raphe nuclei in the hindbrain, whereas in the periphery 5-HT is mainly synthesized in ECs in the intestine and distributed by platelets in the circulation (Box 1). However, local 5-HT generation in enteric neurons, fat, lung, and pancreas has been described and may contribute to its local actions.

The serotonergic signaling system in vertebrates is very complex and is composed of multiple transporters (serotonin transporter, SERT; vesicular monoamine transporter, VMAT) and seven families of 14 receptor subtypes (5-HT₁–₇) [10]. 5-HT biosynthesis and metabolism are described in Box 1 and Figure 1. The initial and rate-limiting step in the biosynthesis of 5-HT is catalyzed by tryptophan hydroxylase (TPH). Together with phenylalanine hydroxylase and tyrosine hydroxylase, TPH constitutes the third member of the highly conserved superfamily of iron- and tetrahydrobiopterin (BH₄)-dependent aromatic amino acid hydroxylases (AAAHs) [11]. Although knockout of the tyrosine hydroxylase gene resulted in an embryonic lethal phenotype [12], genetic ablation of what was then known as TPH (now TPH1) unraveled the existence of a second isoform (TPH2), exposed by the finding of normal 5-HT levels in the brain of Tph1¹⁻/⁻ mice [13]. This newly found duality of the 5-HT system with two independently generated pools of 5-HT—one in the brain and another in the blood—was once more confirmed when targeted deletion of Tph2 reduced brain 5-HT to below 1% without changing circulating 5-HT levels [14–16]. Interestingly, homozygous Tph¹⁻/⁻ mice are alive, healthy, and fertile, but 5-HT concentration in blood remains ~10% of the amount reported in wild-type mice. These

Highlights

5-HT is synthesized by two tryptophan hydroxylases, TPH1 in ECs of the gut and TPH2 in hindbrain raphe nuclei. EC-derived 5-HT is transported by circulating platelets and released upon their activation. Moreover, there is local TPH1 and 5-HT synthesis in lung, pancreatic β cells, and adipocytes, as well as local TPH2-mediated 5-HT synthesis in enteric neurons. TPH1-derived 5-HT causes the gastrointestinal symptoms associated with carcinoid tumors (carcinoid syndrome) and is thought to be involved in several other disorders such as pulmonary hypertension, inflammatory and fibrotic diseases, thrombosis, and obesity. Its effects on osteoporosis are controversial.

Inhibition of peripheral 5-HT synthesis is a novel therapeutic strategy for these diseases. TPH2-mediated 5-HT synthesis in the brain should be spared because its inhibition would cause adverse effects such as depression.

Telotristat ethyl is the first TPH inhibitor with FDA approval for the treatment of carcinoid syndrome. This and other compounds of this novel drug class need to prove their efficacy for the treatment of other diseases in future preclinical and clinical studies.

The clinical use of telotristat ethyl and other non-selective TPH inhibitors will clarify whether their exclusion from the brain is sufficient to avoid adverse central nervous system effects, or if it will be necessary to develop novel compounds which do not inhibit TPH2. The first such TPH1-selective compounds were recently discovered, but their allosteric mechanisms of action and efficacy remain to be further validated.
residual amounts of 5-HT are also still found in the blood of knockout mice lacking both TPH1 and TPH2 [14], giving rise to the idea that phenylalanine hydroxylase may be another source of 5-HT synthesis in vivo because it is known that the enzyme is able to catalyze the hydroxylation of tryptophan to 5-hydroxytryptophan in vitro [17].

TPH1 and TPH2 are highly homologous proteins, but differ in their kinetic properties and, more notably, in their tissue distribution [18,19]. TPH2 is predominantly expressed in raphe neurons of the brainstem [15,18] and myenteric neurons in the gut [20,21], and is considered to be the source of the central neurotransmitter pool of 5-HT. The majority of blood 5-HT is synthesized by TPH1-expressing ECs of the gastrointestinal (GI) tract and enters the circulation packed in dense granules of thrombocytes where it mediates its hormonal actions upon platelet release at the site of activation. TPH1 is also found in other peripheral tissues such as pancreas, fat, and lung, as well as in the pineal gland where 5-HT serves as a precursor molecule for melatonin biosynthesis (Figure 1) [4,18,20]. TPH2 expression in enteric neurons does not noticeably contribute to the peripheral 5-HT pool because, as mentioned above, mice lacking both TPH1 and TPH2 exhibit the same blood concentrations of the monoamine as TPH1-deficient animals [14]. Likewise, TPH1 expression in the pineal gland does not contribute to the central 5-HT pool because TPH2-deficient animals have less than 1% of normal 5-HT levels in the brain [16].

Figure 1. Metabolism of Serotonin (5-HT). Tryptophan hydroxylases TPH1/2 catalyze the conversion of the essential amino acid L-tryptophan (Trp) to 5-hydroxytryptophan (5-HTP) in the presence of molecular oxygen and the cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4). 5-HTP is further converted to 5-HT by aromatic amino acid decarboxylase (AADC). 5-HT can be metabolized to melatonin by serotonin N-acetyltransferase (SNAT) and hydroxyindole O-methyltransferase (HIOMT), or degraded to 5-hydroxyindole acetic acid (5-HIAA) by monoamine oxidase A (MAO-A) and aldehyde dehydrogenase (ALDH).
In the past, therapeutics involving the serotonergic system only targeted 5-HT transporters and receptors, and were mostly aimed at central indications such as depression, psychosis, and migraine [22–24]. Nevertheless, the dualistic character of the 5-HT system, enforced by the inability of 5-HT to freely cross the blood–brain barrier in either direction, gave rise to the opportunity to pharmacologically target central and peripheral 5-HT biosynthesis in an independent manner. Advances and ideas in exploring TPH2 as a novel drug target have been comprehensively reviewed [25–27].

Analysis of Tph1−/− mice showed that an imbalance in peripheral 5-HT metabolism is associated with different diseases and pathophysiological processes such as GI disorders, pulmonary arterial hypertension (PAH), fibrosis, and inflammation. Most of these associated diseases are multifaceted in origin, which makes an effective treatment a challenge and has hampered the development of potent therapeutics because of the lack of knowledge of specific disease mechanisms and the non-applicability of the ‘one drug, one target, one indication’ paradigm. However, owing to the increasing medical need to treat multi-morbid patients, the pharmaceutical industry itself has suggested a new strategy – to address targets which influence common pathophysiological mechanisms, such as inflammation, angiogenesis, fibrosis, and cellular proliferation (all of which are linked to 5-HT), that are of therapeutic relevance in several diseases [28]. Hence in this review we aim to collect recent insights into TPH inhibitor drug development (Table 1) as well as first clinical studies (Supplemental information online) that consider peripheral, non-neuronal 5-HT biosynthesis as a novel therapeutic target.

Development of Inhibitors of TPH1

Even before the discovery of TPH2, naturally occurring unspecific inhibitors of TPH (and indoleamine metabolism) have been reported, including dopamine-derived tetrahydroisoquinolines such as salsolinol [29] and tetrahydropapaverine [30], and the food-derived carcinogenic heterocyclic amines Trp-P-1 and Trp-P-2 [31] (Supplemental information online). The low molecular weight phenylalanine analogs p-chlorophenylalanine (fenclonine, PCPA) and p-ethylphenylalanine (PEPA) (Supplemental information online) were the first TPH inhibitors to be studied in vivo. PCPA has been used to treat patients with carcinoid syndrome and chemotherapy-induced emesis, but the compound was not suitable for therapeutic use because of unwanted central nervous system (CNS)-mediated side effects and its general ability to inhibit all members of the AAAS family [32,33]. PEPA is a more potent TPH inhibitor that showed less inhibitory activity towards phenylalanine hydroxylase and tyrosine hydroxylase, but again significantly reduced 5-HT concentration in the brain following intraperitoneal injection, which also restricted its therapeutic potential [34].

Since the functional classification of the TPH isoforms in 2003, both academia and the pharmaceutical industry have worked on establishing TPH1 as a pharmacological target (Figure 2), and the list of filed patents for novel small-molecule compounds inhibiting TPH to treat 5-HT-associated diseases is growing constantly (Box 2). Virtual and in vitro screening approaches were enabled by the successful production of functional TPH1 and TPH2 proteins within recombinant expression systems and the subsequent collection of X-ray co-crystal structures in the Protein Data Bank.

Lexicon Pharmaceuticals were the first to discover and characterize a novel series of substituted phenylalanine derivatives that selectively inhibit 5-HT biosynthesis in the GI tract [35]. The therapeutically essential selectivity for peripheral 5-HT inhibition can be achieved by developing inhibitors that either only act locally in ECs of the gut from the luminal side without entering the

Glossary

5-Hydroxytryptamine (5-HT): another name for serotonin. There are seven families of receptors for 5-HT, 5-HT1 to 5-HT7.

Bleomycin: a chemotherapeutic drug used in cancer treatment. Treatment is limited by the most important adverse effect, pulmonary fibrosis. This side effect is used in animal models of pulmonary fibrosis induced by intratracheal application of the drug.

Carcinoid syndrome: neuroendocrine tumors (NETs) of the gut often generate high amounts of 5-HT and other mediators, and thereby cause carcinoid syndrome, in particular after metastasizing to the liver.

Irritable bowel syndrome (IBS): IBS is characterized by abdominal pain and altered patterns of bowel movements with unknown etiology, which occur over a long time and lead to frequent diarrhea or constipation.

Pulmonary arterial hypertension (PAH): a rare lung disease with high mortality, characterized by increased pulmonary arterial pressure and remodeling, as well as by right ventricular hypertrophy.


Serotonylation: a receptor-independent intracellular signaling mechanism in which 5-HT is covalently bound to small GTPases by transglutaminase 2.

Telotristat ethyl: the free base form of the hippurate salt telotristat etiprate. Also referred to as LX-1032, LX-1606, and LP-778914. The first FDA-approved TPH inhibitor drug (Kemoele®).

Telotristat etiprate: hippurate salt form of telotristat ethyl.

Tryptophan hydroxylase (TPH): the first and rate-limiting enzyme in 5-HT synthesis from tryptophan. There are two isoforms, TPH1 in enterochromaffin cells (ECs) of the gut, and TPH2 in raphe nuclei in the brain.
bloodstream, are unable to cross the blood–brain barrier, or do not inhibit TPH2 (Table 2). However, most inhibitors developed so far are non-selective and equally block TPH1 and TPH2, probably owing to the very high homology between the two enzymes at the active site [18]. The new TPH inhibitors of Lexicon (e.g., LP-521834, LP-534193, LP-533401 and its active enantiomer LP-923941, LP-615819 and its active enantiomer LP-920540; Supplemental information online) were found to competitively bind to the tryptophan pocket of both TPH isoforms [36] and selectively reduce peripheral 5-HT levels in mice after oral administration by 50% because of their inability to penetrate the blood–brain barrier [37,38]. LX-1031 and the more potent back-up compound LX-1033 (Supplemental information online) were specifically optimized for restricted TPH inhibition in ECs of the GI tract because they do not pass the

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Disease model (species)</th>
<th>Administration</th>
<th>Effect</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP-615819</td>
<td>Cisplatin-induced emesis (ferret)</td>
<td>20, 60, and 180 mg/kg twice daily oral gavage for 5 days</td>
<td>Non-significant 50% reduction in emesis severity</td>
<td>[35]</td>
</tr>
<tr>
<td>LP-533401</td>
<td>High-fat diet-induced obesity (mouse)</td>
<td>100 mg/kg daily by gavage for 12 weeks</td>
<td>Improved metabolic parameters; no change in weight gain</td>
<td>[76]</td>
</tr>
<tr>
<td>LP-533401</td>
<td>High-fat diet-induced obesity (mouse)</td>
<td>25 mg/kg daily by intraperitoneal injection for 12 weeks</td>
<td>Reduced gain of weight and fat; improved metabolic parameters</td>
<td>[74]</td>
</tr>
<tr>
<td>LP-923941b</td>
<td>Osteoporosis (ovariectomy in mouse and rat)</td>
<td>1–250 mg/kg daily in diet for 28 days</td>
<td>Normalization of bone mass</td>
<td>[116]</td>
</tr>
<tr>
<td>LP-533401</td>
<td>Osteoporosis (ovariectomy in mouse)</td>
<td>5–25 mg/kg daily in diet for 6 or 12 weeks</td>
<td>Increase in bone mass</td>
<td>[126]</td>
</tr>
<tr>
<td>LP-923941c</td>
<td>Osteoporosis (ovariectomy in mouse and rat)</td>
<td>250 mg/kg daily by oral gavage for 28 days</td>
<td>No significant effect on bone mass</td>
<td>[119]</td>
</tr>
<tr>
<td>LX-1606c</td>
<td>Bone loss (rat strain with high platelet 5-HT)</td>
<td>25 mg/kg daily by oral gavage for 36 days</td>
<td>Non-significant increase in bone mass</td>
<td>[127]</td>
</tr>
<tr>
<td>LP-920540f</td>
<td>Necrotizing enterocolitis (mouse)</td>
<td>200 mg/kg daily by gavage for 5 days</td>
<td>Reduced weight loss; improved survival and histology</td>
<td>[70]</td>
</tr>
<tr>
<td>LP-920540f and LX-1032c</td>
<td>Trinitrobenzene sulfonic acid-induced colitis (mouse)</td>
<td>30 mg/kg daily LP-920540f for 5 days; 200 mg/kg daily LX1032c for 5 days</td>
<td>Reduced weight loss; improved stool consistency and histology</td>
<td>[72]</td>
</tr>
<tr>
<td>LX-1606c</td>
<td>Dextran sulfate-induced colitis (mouse)</td>
<td>300 mg/kg daily oral gavage for 5 or 6 days</td>
<td>Delayed onset and severity</td>
<td>[71]</td>
</tr>
<tr>
<td>LX-1606c</td>
<td>Trichuris muris-induced colitis (mouse)</td>
<td>300 mg/kg daily oral gavage for 14 or 21 days</td>
<td>Enhanced worm expulsion and goblet cell number</td>
<td>[71]</td>
</tr>
<tr>
<td>KAR5585 and KAR5416</td>
<td>Pulmonary hypertension (rat)</td>
<td>100 or 200 mg/kg daily by oral gavage for 28 days</td>
<td>Reduced pulmonary arterial pressure, vessel wall thickness, and occlusion</td>
<td>[45]</td>
</tr>
<tr>
<td>mol002291</td>
<td>Trinitrobenzene sulfonic acid-induced colitis (rat)</td>
<td>40, 80, or 160 mg/kg daily for 3 weeks</td>
<td>Decreased visceral hyperalgesia</td>
<td>[46]</td>
</tr>
</tbody>
</table>

*Studies using PCPA were excluded owing to the nonspecific effects of this drug.
*Active enantiomer of LP-533401.
*New referred to as telotristat ethyl.
*Active enantiomer of LP-615819.
intestinal barrier and were the first compounds to enter clinical trials for GI diseases such as irritable bowel syndrome (IBS; Supplemental information online) [39]. In parallel, telotristat ethyl (also known as LX-1032/LX-1606/telotristat etiprate; Supplemental information online) was developed to inhibit 5-HT in the periphery but not in the brain because it enters the bloodstream but cannot pass the blood–brain barrier. It has recently been approved by the FDA as the first small-molecule, peripheral TPH inhibitor to treat carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults [40,41]. Karos Pharmaceuticals used a structure-based design methodology approach to further develop the structural scaffolds of the Lexicon compounds, and discovered a new class of peripherally restricted TPH inhibitors that lack the characteristic phenylalanine moiety [42,43]. These spirocyclic proline-based TPH1 inhibitors were chemically and pharmacokinetically optimized (KAR5585, KAR5417; Supplemental information online) [44], successfully tested in vivo [45], and have already entered a Phase I first-in-human study (Supplemental information online).

Recent publications claim to have discovered the first specific inhibitors of TPH1. High-throughput, docking-based, virtual screening of a Traditional Chinese Medicines database identified 1-galloypedunculagin (mol002291, Supplemental information online) as a potential TPH inhibitor, a molecule derived from the Chinese herb Rheum officinale. The molecule specifically inhibited TPH1 in vitro and reduced colonic 5-HT content, and also attenuated visceral hyperalgesia in vivo [46] (Table 1). Another recently published Novartis-funded study featured in vitro and in vivo efficacy data of a novel allosteric TPH1-selective inhibitor that was found in a high-throughput proximity assay screen [47]. An overview of the in vivo effects of the
newly discovered TPH inhibitors in different disease models and in clinical trials is given in Table 1.

**5-HT Function and Therapeutic Implications in Peripheral Organs**

**Cancer**

Multiple studies have found an involvement of 5-HT in tumor biology and cancer progression, influencing tumor growth, angiogenesis, and cancer cell differentiation and migration in the affected organs [48]. Among the most prominent examples are neuroendocrine tumors (NETs),
a genetically and clinically heterogeneous group of GI, pancreatic, and bronchial tumors. Upon systemic release of different hormonal mediators and vasoactive amines, NETs are able to induce a series of symptoms, called carcinoid syndrome, characterized by diarrhea, cutaneous flushing, wheezing, bronchoconstriction, cardiac valve disease, and mesenteric fibrosis [49]. Carcinoid syndrome is associated with up to 80% of GI NETs and about 1% of pancreatic NETs [41]. These mainly metastatic carcinoid tumors overexpress TPH1 and excessively secrete 5-HT into circulation [50], where it is involved in the development of acute and chronic pathophysiologic symptoms [33,49]. Thus, carcinoid syndrome became the first indication that was successfully targeted by an FDA-approved oral, small-molecule inhibitor of TPH1 (telotristat ethyl; Supplemental information online) [41,51]. Several Phase II and Phase III clinical trials have proven the safety and efficacy of this drug to alleviate the symptoms of this disease (Supplemental information online) [52–55].

The high 5-HT-synthesizing activity in NETs can also be exploited to inhibit their growth by applying the TPH inhibitor and suicide compound, 7-hydroxytryptophan, which is converted to the toxin 5,7-dihydroxytryptamine in TPH- and AADC-expressing cells (Figure 1) [56,57]. This strategy was successfully employed in vitro, but so far there are no published in vivo studies.

Elevated 5-HT levels, resulting from increased TPH1 and decreased expression of the 5-HT-degrading enzyme MAO-A (Figure 1), are also found in pancreatic ductal adenocarcinoma (PDAC), and correlated with cancer stage and patient survival time [58]. The same group also showed 5-HT-dependent tumor growth in PDAC-derived xenografts in mice [58]. Furthermore, malignant breast cancer progression was shown to be accompanied by increased TPH1 expression, 5-HT production and alterations in 5-HT receptor expression and signaling, leading to stimulated proliferation and resistance to apoptosis [59,60]. In vitro studies with MDA-MB-231, a cell line derived from a highly aggressive breast cancer subtype called triple-negative breast cancer, showed elevated expression levels of TPH1, which were further augmented upon 5-HT treatment. The stimulatory effect of 5-HT on MDA-MB-231 cells promoted invasion and proliferation via different downstream signaling pathways of the 5-HT7 receptor, suggesting a stronger influence during the first stage of metastasis (invasion and migration) than during the later proliferative phase [61]. In addition to antagonists of SERT and 5-HT receptors, the TPH1 inhibitor LP-533401 reportedly compromised the activity of breast tumor initiating cells in a functional sphere-forming in vitro assay [62].

Not only tumor cells but also tumor-infiltrating macrophages are targets of 5-HT. 5-HT deficiency in Tph1−/− mice leads to increased generation of angiostatin in these cells, which inhibits the growth of tumor-supporting vessels [63]. Thus, peripheral 5-HT could represent a target for the treatment of several cancers, and TPH inhibitors might be of therapeutic use to prevent cancer progression into invasive and metastatic forms which are associated with poor prognosis.

GI Diseases
In the periphery, GI diseases are the only disorders for which serotonergic drugs are already in clinical use. 5-HT3 antagonists are used as anti-emetics and, together with 5-HT4 agonists, they are also effective drugs for IBS [64]. The predominance of the gut as a target for serotonergic drugs is not surprising because the gut and its ECs express nearly all TPH1 in the body and are therefore the most important source of 5-HT in the organism. Surprisingly, Tph1−/− mice thrived normally and did not confirm the expected essential function of EC-derived 5-HT in gut mucosal integrity, motility, and/or secretion [13,14,65,66]. Nonetheless, one study found significant impairments in colonic propulsion and peristaltic reflexes [67]. TPH2
in myenteric neurons seems to be more important for gut motility because it was shown to be altered in Tph2<sup>-/-</sup> mice [65,66]. Nevertheless, 5-HT synthesis in the gut was suggested as a target for GI diseases such as IBS. Accordingly, Tph1<sup>-/-</sup> mice and animals treated with LP-920540 or telotristat ethyl are protected in several different colitis models, including necrotizing enterocolitis and colitis induced by oral dextran sulfate sodium administration or trinitrobenzene sulfate, as well as in an infection-induced intestinal inflammation model [68–72] (Table 1). Based on these results, a Phase II clinical trial with LX-1031 was performed in diarrhea-predominant IBS, and slight but significant symptom relief was achieved in the patients (Supplemental information online) [39,73]. Thus, TPH inhibitors may be promising drugs for the treatment of inflammatory bowel diseases.

**Obesity and Diabetes**

Two recent seminal studies with Tph1<sup>-/-</sup> mice suggest a central role of peripheral 5-HT in obesity [74,75]. Tissue-specific knockout models revealed that TPH1 in adipocytes and local 5-HT generation in the fat is more important for resistance against a high-fat diet than is EC-derived 5-HT [75,76]. The absence of 5-HT or TPH inhibition by LP-533401 facilitated norepinephrine-induced browning and stimulated thermogenesis in brown adipocytes [74,75], explaining their anti-obesity effect (Table 1).

Moreover, improved glucose tolerance and increased glucose uptake, at least in some tissues, was observed in mice deficient in TPH1 and after LP-533401 treatment [74–76] (Table 1). On the other hand, insulin secretion of pancreatic β cells is dependent on serotonylation of small G proteins, and is therefore impaired in Tph1<sup>-/-</sup> mice [77]. Again, local generation of TPH1 and 5-HT is pivotal for the phenotype, as shown by a β cell-specific Tph1 knockout mouse [78]. This local 5-HT synthesis is also essential for the adaptation of insulin-producing cells to the additional needs during pregnancy [79].

Because most of these metabolic effects have not only been seen in Tph1<sup>-/-</sup> mice but also after treatment with TPH inhibitors, these compounds have potential as novel anti-obesity or anti-diabetic drugs. However, whether TPH1 inhibition in pancreatic β cells may have deleterious effects, in particular in pregnancy, needs further clarification.

**Thrombosis and Inflammation**

The first phenotype observed in Tph1<sup>-/-</sup> mice was a prolonged tail bleeding time [80]. The reason for this phenotype was impaired release of von Willebrand factor and other proteins from platelet α granules, hampering platelet aggregation and adhesion to the basal membrane, and consequently thrombus formation [80,81]. Accordingly, Tph1<sup>-/-</sup> mice were protected from thrombosis induced by endothelial damage or treatment with epinephrine and collagen [80]. Mechanistically, 5-HT activates the release of platelet α granules in two interconnected ways—binding to the 5-HT<sub>2A</sub> receptor on the plasma membrane and serotonylation of small G proteins after uptake by SERT into the cytoplasm [80].

Platelets are the main source of 5-HT in the periphery, and release it at sites of injury and inflammation, with marked effects on cells of the immune system. Neutrophils in particular seem to react to platelet-derived 5-HT in inflammation because neutrophil-driven shock states are less pronounced in Tph1<sup>-/-</sup> mice and in animals treated with PCPA [82–85]. In addition, other cell types of the immune system may also be responsive to platelet-derived 5-HT, such as dendritic cells. In Tph1<sup>-/-</sup> mice this leads to reduced allergic airway inflammation as a result of defective T cell priming [86]. Moreover, postoperative abdominal adhesion formation, which is
also thought to be an inflammatory process, was reduced in $Tph1^{-/-}$ and PCPA-treated mice [87].

However, in acute pancreatitis $Tph1^{-/-}$ mice exhibit a dual phenotype: they are protected from early inflammation based on attenuated leukocyte infiltration, but for so far unknown reasons show accelerated disease progression [88]. An aggravated pathology in $Tph1^{-/-}$ mice was also reported for other inflammation models such as autoimmune arthritis [89] and experimental autoimmune encephalitis (a model of multiple sclerosis) [90]. Thus, the use of TPH inhibitors in inflammatory diseases will probably be restricted to specific disease entities which need to be defined by further preclinical and clinical studies.

**Fibrosis**

Systemic fibrotic diseases (e.g., systemic sclerosis) and organ-specific fibrosis (e.g., kidney fibrosis, idiopathic pulmonary fibrosis, liver cirrhosis) share pathogenetic mechanisms. In all these diseases, activated fibroblasts release augmented amounts of extracellular matrix that disrupt tissue structure, leading to organ dysfunction and to high morbidity and mortality in affected patients [91]. 5-HT is released upon activation of platelets and is elevated in the blood of systemic sclerosis patients [6]. More than 50 years ago a pathogenetic role of 5-HT in tissue fibrosis was postulated based on observations in carcinoid patients with increased blood 5-HT [92,93]. Moreover, patients and mice with lung fibrosis exhibit upregulated expression of 5-HT$_{2A}$ receptors, and lung 5-HT is increased in bleomycin-treated mice [94,95]. Furthermore, 5-HT$_{2A/B}$ receptor antagonists exert antifibrotic effects in the same [94,96] and other animal models of tissue fibrosis [95,97]. In a mouse model of systemic sclerosis, 5-HT levels are also elevated, and genetic deficiency of 5-HT$_{2B}$ receptors or of TPH1 reduced dermal fibrosis [95]. In addition to the circulating 5-HT, local biosynthesis of 5-HT occurs in the lung itself, contributing to tissue 5-HT levels. Accordingly, in the bleomycin-induced lung fibrosis rat model, lung 5-HT levels and synthesis were correlated with lung $Tph1$ mRNA levels, suggesting a contribution from local 5-HT synthesis [98].

Thus, 5-HT in peripheral tissues consistently promotes fibrotic diseases, and therefore TPH inhibition is promising as a novel therapeutic strategy against these diseases.

**Pulmonary Arterial Hypertension**

There is ample evidence that 5-HT plays a major role in the pathogenesis of PAH. Accordingly, appetite-suppressants releasing 5-HT, such as fenfluramine, had to be retracted from the market because of an unacceptably high rate of drug-induced PAH [99]. Patients and animals with platelet storage disease and thereby increased plasma 5-HT levels often develop PAH [100,101]. Moreover, there is evidence for local expression of TPH1 and local 5-HT synthesis in the lung, with significant impact on the pathogenesis of PAH [102,103]. Genetic depletion of TPH1 protects mice from experimentally induced PAH [103–107]. Moreover, overexpression of SERT in lung arteries causes PAH [108], and patients with PAH show increased 5-HT levels in lung and blood [109]. Very recently, it has been shown that TPH inhibition ameliorates PAH in two different animal models [45] (Table 1).

Therefore, PAH is most likely one of the next disease indications for which TPH inhibitors will be tested in clinical trials, in particular because PAH is a rare disease, which will facilitate regulatory approval of this application.
Liver Diseases
In the liver the effects of 5-HT are bivalent. It has been shown that \( Tph1^{-/-} \) mice cannot regenerate their liver after resection or ischemia–reperfusion damage [110,111]. In addition, these mice are also more severely affected by liver injury through bile duct ligation or acetaminophen treatment [112,113]. However, in a nonalcoholic steatohepatitis model, \( Tph1^{-/-} \) mice are protected due to reduced generation of reactive oxygen species [114]. The same is true for viral hepatitis; in this case the effects of platelet 5-HT on the microcirculation and subsequent virus elimination are causative [115].

Thus, the use of TPH inhibitors in liver diseases depends on the etiology of the disease, and needs further preclinical and clinical evaluation.

Osteoporosis
The most prominent example for the therapeutic use of TPH inhibitors was published in 2010, showing that osteoporosis could be blunted in rodent models by LP-533401 [116] (Table 1). These experiments were based on findings of the same group that mice deficient in EC TPH1 develop increased bone density [117]. This group also showed a reduced bone mass phenotype in \( Tph2^{-/-} \) mice, and postulated a mechanism by which TPH2-derived 5-HT stimulates bone growth, in contrast to 5-HT synthesized by TPH1 in the gut, which blocks it [118]. However, there are also conflicting studies by other authors which do not show effects of LP-923941 (the active enantiomer of LP-533401) on osteoporosis in animal models [119,120] (Table 1). Moreover, bone loss in a rat periodontitis model could not be inhibited by LP-533401 [121] (Table 1). There has been a public debate about these inconsistencies [122,123], but the reasons for the discrepant results have not yet been resolved. Therefore, the therapeutic application of TPH inhibitors in osteoporosis remains controversial, and further (clinical) studies will be necessary to clarify the issue.

Concluding Remarks and Future Perspectives
The duality of the serotonergic system in vertebrates, revealed by the discovery of the neuron-specific TPH2 through \( Tph1^{-/-} \) mice [13], has paved the way for directed interference with central and peripheral 5-HT functions. Pathophysiological processes in several complex disorders such as carcinoid tumors, PAH, and IBS are associated with gut-derived and/or locally synthesized 5-HT. Consequently, TPH1 emerged as a possible therapeutic target for the development of inhibitors. In February 2017 the drug telotristat ethyl (Xermelo\textsuperscript{TM}, Lexicon Pharmaceuticals) was the first-in-class, small-molecule, peripheral TPH inhibitor to be approved in the USA for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy [40]. This shows that the diversity of 5-HT actions constitutes a challenge as well as an opportunity because many of the disorders mentioned in this review lack adequate therapy because of their multifaceted pathophysiology. Hence it is anticipated that a (co-)treatment with TPH inhibitors might also be beneficial in other inflammatory and fibrotic diseases, where a combination of different treatment options seems to be a promising way to improve therapeutic outcome. However, owing to the essential role of TPH1-derived 5-HT in embryo development [2,3], and in the adjustment of maternal insulin production [79] and mammary gland function [124], the use of TPH inhibitors in pregnant and lactating women needs further investigation (see Outstanding Questions). Moreover, it remains to be clarified whether it is sufficient to avoid adverse CNS effects of TPH inhibitors by using drugs reported to not pass the blood–brain barrier, such as telotristat ethyl, because the exclusion from the brain may not be complete. Alternatively, it may be necessary to develop novel compounds which do not inhibit TPH2 [46,47]. However, based on the very high homology between TPH1 and TPH2, in particular at the active site, the development of selective drugs will be a challenge.

Outstanding Questions
Will it be possible to generate efficient TPH1-specific inhibitors or is it sufficient to have drugs that do not pass the blood–brain barrier?
Will TPH inhibition also fulfill the promises, based on animal studies, in clinical trials – in particular in pulmonary hypertension, fibrotic disease, and osteoporosis?
Will TPH inhibition be a safe treatment without intolerable side effects, and will it be acceptable to treat pregnant or lactating women?
It is expected that the use of the novel TPH inhibitors in preclinical disease models as well as the deep phenotyping of TPH knockout mice will reveal additional indications for the use of these drugs. Moreover, such studies may reveal the downstream pathways by which 5-HT acts, and thereby unravel novel targets for pharmacological intervention for particular diseases.

Acknowledgments
Research by the authors was supported by grants of the German Ministry for Education and Research (16V0276 and the DZHK, German Centre for Cardiovascular Research).

Supplemental Information
Supplemental information associated with this article can be found online at https://doi.org/10.1016/j.tips.2018.03.004.

References
29. Ota, M. et al. (1992) Inhibition of tryptophan hydroxylase by (R)- and (S)-1-methyl-6,7-dihydroxy-2,3,4-tetrahydroisquino- lines (talocinole). Neuropharmacology 31, 337–341
68. Ghia, J.E. et al. (2009) Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 137, 1649–1660
76. Sumara, G. et al. (2012) Gut-derived serotonin is a multifunc tional determinant to fasting adaptation. Cell Metab. 16, 568–600


